Seminars in Oncology
Volume 33, Supplement 12 , Pages 8-17, December 2006

Maximizing the Delivery of Intraperitoneal Therapy While Minimizing Drug Toxicity and Maintaining Quality of Life

  • David S. Alberts

      Affiliations

    • Dr Alberts has received grant and research support from and serves on the speakers bureau for MedImmune, Inc. He is also a paid consultant for Amgen Inc.
    • Corresponding Author InformationAddress reprint requests to David S. Alberts, MD, Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ 85274.
    • ,
  • Ardie Delforge

Arizona Cancer Center, Tucson, AZ.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This activity is supported by an unrestricted educational grant from MedImmune Oncology, Inc., a subsidiary of MedImmune, Inc.

PII: S0093-7754(06)00425-8

doi:10.1053/j.seminoncol.2006.11.003

Seminars in Oncology
Volume 33, Supplement 12 , Pages 8-17, December 2006

Article Tools